This study used a gene panel sequencing approach to screen a consecutive series of unselected New Zealand female breast cancer patients for pathogenic variants in any of six high-risk breast cancer susceptibility genes (BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53) and subsequently assessed the identified carriers for their eligibility for testing using national guidelines. This evidence concerns the gene CDH1 and breast carcinoma.